Swiss-based Limula raised over €6.2 million aiming to democratise access to life-saving cell and gene therapies
Summary
Life science startup Limula announced today that it has raised over €6.2 million to advance their solution for automating cell therapy manufacturing to the next stage of development. The trio witnessed that outdated manufacturing methods were a speed bump to the adoption of Cell and Gene Therapy products—like chimeric antigen receptor (CAR) T-cells. By combining the functionalities of a bioreactor and a centrifuge into one single closed vessel, Limula’s proprietary solution can handle a wide range of volumes and cell numbers, removing transfer steps and therefore limiting stress, losses, and potential contamination. These two aspects are key to unlocking the full potential of Cell and Gene Therapy, making them accessible to the many, not just the few.” Limula’s founders built a high-performing multidisciplinary team, most recently joined by domain experts Olivier Waridel, former CEO of Cytiva-owned Biosafe, Caroline Boudousquié, former Head of Process Development at the Center for Experimental Therapeutics (CTE) of the University Hospital in Lausanne, and Maria Elena Grisostolo, former VP Operations at Lunaphore. Prof. Bernhard Gentner at the San Raffaele Telethon Institute for Gene Therapy said: “We believe the solution Limula is advancing can support our current process development activities and later enable the manufacturing of these cell products at scale.